References
Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics 2005; 23 (12): 1271–1282
Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess 2006; 10 (1): iii–iv, ix-xi, 1-160
Bosanquet N, Yeates A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease Detter]. Pharmacoeconomics 2006; 24 (6): 623–625
National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk/page.aspx?O=appraisals.inprogress.alzheimersdisease [Accessed 2006 May 19]
Acknowledgements
The authors have no conflicts of interest relevent to the content of this reply.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Green, C., Picot, J., Loveman, E. et al. The Authors’ Reply. Pharmacoeconomics 24, 625–626 (2006). https://doi.org/10.2165/00019053-200624060-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200624060-00009